<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1139-7632</journal-id>
<journal-title><![CDATA[Pediatría Atención Primaria]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Pediatr Aten Primaria]]></abbrev-journal-title>
<issn>1139-7632</issn>
<publisher>
<publisher-name><![CDATA[Asociación Española de Pediatría de Atención Primaria]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1139-76322024000200011</article-id>
<article-id pub-id-type="doi">10.60147/65f4086d</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[¡Atención, atención: hígado y bazo grandes!]]></article-title>
<article-title xml:lang="en"><![CDATA[Attention, attention: big liver and large spleen!]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carrillo-Pérez]]></surname>
<given-names><![CDATA[Noelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Alba-Romero]]></surname>
<given-names><![CDATA[Concepción]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carabaño-Aguado]]></surname>
<given-names><![CDATA[Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario 12 de Octubre Servicio de Pediatría Sección de Gastroenterología, Hepatología y Nutrición Pediátrica]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario 12 de Octubre Servicio de Neonatología ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>26</volume>
<numero>102</numero>
<fpage>189</fpage>
<lpage>191</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1139-76322024000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1139-76322024000200011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1139-76322024000200011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[ Resumen El síndrome mieloproliferativo transitorio (SMPT) es una anomalía hematológica característica de los pacientes con síndrome de Down y que aparece en el periodo neonatal. Se caracteriza por presentar una gran leucocitosis en sangre periférica, a expensas de leucocitos de morfología anómala (blastos). Los pacientes suelen estar asintomáticos. En un pequeño porcentaje, el SMPT puede manifestarse como cuadros graves derivados de la infiltración de estas células en diferentes órganos, entre ellos el hígado y el bazo. La hepatoesplenomegalia, de hecho, es un &#8220;signo guía&#8221; de gran utilidad para iniciar su proceso diagnóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ Abstract Transient myeloproliferative syndrome (TMPS) is a hematological abnormality characteristic of patients with Down syndrome. It appears in the neonatal period. It is characterized by a large leukocytosis in peripheral blood, at the expense of leukocytes of abnormal morphology (blasts). Patients are usually asymptomatic. In a small percentage, TMPS can manifest as severe symptoms derived from the infiltration of these cells into different organs, liver included. Hepatosplenomegaly, in fact, is a very useful guiding sign to start the diagnostic process.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Esplenomegalia]]></kwd>
<kwd lng="es"><![CDATA[Hepatomegalia]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de Down]]></kwd>
<kwd lng="es"><![CDATA[Síndrome mieloproliferativo transitorio]]></kwd>
<kwd lng="en"><![CDATA[Down syndrome]]></kwd>
<kwd lng="en"><![CDATA[Hepatomegaly]]></kwd>
<kwd lng="en"><![CDATA[Splenomegaly]]></kwd>
<kwd lng="en"><![CDATA[Transient myeloproliferative syndrome]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kalev-Zylinska]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in molecular characterization of myeloid proliferations associated with Down syndrome]]></article-title>
<source><![CDATA[Front Genet]]></source>
<year>2022</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tunstall]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatnagar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Norton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[O'Marcaigh]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2018</year>
<volume>182</volume>
<page-range>200-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome]]></article-title>
<source><![CDATA[Pediatr Int]]></source>
<year>2019</year>
<volume>61</volume>
<page-range>222-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Telman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sosnowska-Sienkiewicz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Strauss]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mazela]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ma&#324;kowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Januszkiewicz-Lewandowska]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why Is Health Care for Children with Down Syndrome So Crucial from the First Days of Life? A Retrospective Cohort Study Emphasized Transient Abnormal Myelopoiesis (TAM) Syndrome at Three Centers]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2022</year>
<volume>19</volume>
<numero>15</numero>
<issue>15</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
